APO-SALVENT 5MG/ML SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

SALBUTAMOL (SALBUTAMOL SULFATE)

可用日期:

APOTEX INC

ATC代码:

R03AC02

INN（国际名称）:

SALBUTAMOL

剂量:

5MG

药物剂型:

SOLUTION

组成:

SALBUTAMOL (SALBUTAMOL SULFATE) 5MG

给药途径:

INHALATION

每包单位数:

10ML

处方类型:

Prescription

治疗领域:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

產品總結:

Active ingredient group (AIG) number: 0108887006; AHFS:

授权状态:

APPROVED

授权日期:

1993-08-11

产品特点

_Page 1 of 32_
PRODUCT MONOGRAPH
PR
APO-SALVENT RESPIRATOR SOLUTIONS
(SALBUTAMOL SULFATE SOLUTIONS BP)
PR
APO-SALVENT RESPIRATOR SOLUTION 50 MG IN 10 ML (5 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 1.25 MG IN 2.5 ML (0.5 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 2.5 MG IN 2.5 ML (1 MG/ML SALBUTAMOL)
PR
APO-SALVENT STERULES 5.0 MG IN 2.5 ML (2 MG/ML SALBUTAMOL)
BRONCHODILATOR,
Β
2
-ADRENERGIC STIMULANT
APOTEX INC.
150 SIGNET DRIVE
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
March 16, 2020
CONTROL # 236795
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................................................................
4
ADVERSE REACTIONS
.............................................................................................................................................
7
DRUG INTERACTIONS
..............................................................................................................................................
8
DOSAGE AND ADMINISTRATION
........................................................................................................................
10
OVERDOSAGE
..........................................................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................